Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing

Executive Summary

CEO pledges transparency and responsible pricing of J&J drugs during the company’s earnings call, while outlining its goals for US health care and tax reform. Fourth quarter performance was unspectacular, although J&J's oncology and immunology portfolios showed sales growth.

You may also be interested in...



J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Boasting of 14 current or near-term blockbusters and success staving off Remicade biosimilars, Johnson & Johnson says its growth derives 100% from sales volume, not price increases. All the same, it continues call for slow pricing reform.

J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says

Bernstein analyst looks into J&J's average net price decline in 2017 and notes average sales price hikes for growth products Darzalex and Imbruvica are offset by price cuts for drugs facing competition. All products had single digit increases, though.

Earnings Winners and Losers: BSX, EW, ABT, JNJ, SYK, ZBH

Many medtech companies reported their sales and earnings for all of 2016, along with projections for 2017, at the end of January or early February. Medtech Insight has examined their reports as well as the comments of the analysts who track these companies to highlight a few that had especially good years, some that had down years, and some lesser-known companies worth watching in the future.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel